One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Call for a global cancer funding collaboration
doi : 10.1016/S1470-2045(25)00161-5
Volume 26, Issue 4, April 2025, Page 399
Non-surgical approach to operable oesophageal cancer: is it prime time yet?
Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting
WHO Classification of Tumours: evolution of a global resource in the molecular era
EUROPA trial: cost implications of radiotherapy versus endocrine therapy
EUROPA trial: cost implications of radiotherapy versus endocrine therapy – Authors' reply
Integrating dental and oral care in oncology: a crucial step towards comprehensive cancer treatment
Re-evaluating anxiety levels and participant characteristics in PATHFINDER
New agreement aims to eliminate cervical cancer across the Americas
UK sees almost 30 000 extra cancer deaths each year due to deprivation
Chemical industry lobbyists will run chemical safety oversight at US EPA
Projected global rise in breast cancer incidence and mortality by 2050
Children and young people with cancer affected by disability benefit delays
Lung cancer treatment compromised by delayed genomic test results
The impact of armed conflict on global patterns of childhood cancer
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis
Innovative, early-phase clinical trials of drug–radiotherapy combinations
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales
